After years of development, Beike Group has become a company with: multiple wholly-owned subsidiaries: Shenzhen Beike, Jiangsu Beike, Anhui Beike, Liaoning Beike, Beike International (Hong Kong), Beike International (Thailand), Beike

Branch International (India), etc.

Strong R&D strength: has applied for 14 invention patents (including 2 international invention patents) and 2 utility model patents; published nearly 100 papers in internationally renowned publications at home and abroad, including stem cell; undertook 27 government projects at all levels

projects, including 3 national-level projects (1 863 project), 14 provincial-level projects, and 10 municipal-level projects. In 2009, it passed the national high-tech enterprise certification and obtained membership of the International Society for Cell Therapy (ISCT).

Strict quality control system: Beike Biotech has always adhered to strict quality management systems and business practices: it is the first enterprise in China’s stem cell field to pass ISO9001 quality management system certification and ISO17025 audit; it is the first company in China to obtain the certification from the International Cell Therapy Association (

ISCT) accredited member unit, indicating that the quality standards of mesenchymal stem cells (MSC) prepared by Beike have reached international standards, and the MSC treatment approved by the US FDA also adopts the same standard; the domestic stem cell industry is the first company to obtain national recognition of China's conformity assessment

A laboratory with qualifications accredited by CNAS; No. 1 in the world: Beike Stem Cell Bank has launched accreditation by the American AABB (American Association of Blood Banks) and FACT (International Cell Therapy Accreditation Foundation), and will become the first accredited laboratory in the world.

Comprehensive stem cell bank.

Huge global clinical research technical support network: It has provided clinical-grade stem cells and stem cell clinical research technical support to more than 70 medical institutions across the country and many countries in Southeast Asia, the Middle East, Europe, etc., and has accumulated the largest and most data-intensive network in the world.

Comprehensive stem cell clinical research safety and effectiveness database.

The largest comprehensive stem cell bank in Asia: The first phase of the stem cell bank includes Jiangsu Stem Cell Bank, Shenzhen Stem Cell Bank and Anhui Stem Cell Bank, with a total construction area of ??30,000M2, a total designed bank capacity of more than 2 million copies, and a total investment of nearly 500 million yuan.

The second phase of construction includes Liaoning Stem Cell Bank, Henan Stem Cell Bank, Guizhou Stem Cell Bank, India Stem Cell Bank and Thailand Stem Cell Bank. The total designed bank capacity after completion will be close to 10 million.

?Beike Biotechnology will adhere to the corporate philosophy of "rigor, innovation, care, and service" to promote stem cell technology to benefit human health and pursue it unremittingly.